Global Hormone Replacement Therapy Market Overview

Global Hormone Replacement Therapy Market Size Was Valued at USD 28.06 Billion in 2021, and is Projected to Reach USD 43.03 Billion by 2028, Growing at A CAGR of 6.3% From 2022 to 2028.

Hormone replacement therapy (HRT) is the usage of hormones to replace natural hormones when the body's hormone production is insufficient. Thyroid and human growth hormone patients, for instance, may get hormone replacement treatment. Furthermore, HRT was often administered to menopausal women for the alleviation of symptoms such as hot flushes, night sweats, sleep difficulties, psychological and Genito-urinary disorders (urinary frequency and vaginal dryness), as well as the prevention of osteoporosis. Hormone replacement therapy has been demonstrated to lessen hot flashes, osteoporosis risk, and other menopausal symptoms in women. Furthermore, due to their expansion in a variety of additional hormone-related illnesses impacting women and men of various ages, these drugs are boosting the market growth. Hormone replacement therapy has gained popularity in recent years attributed to the ease of administration and the growing number of patients suffering from illnesses such as growth deficit, thyroid disorders, and others thus driving worldwide hormone replacement therapy market expansion over the forecast period.

Market Dynamics And Key Factors for the Hormone Replacement Therapy Market

Drivers:

If women begin HRT around menopause, the risk is very low, and it appears to provide cardiovascular and bone-protective benefits. Although it is not recommended that women over the age of 60 begin HRT, the WHI trial found that those who do so do not seem to be at an elevated risk of cardiovascular events or mortality. Moreover, HRT also alleviates menopause-related illnesses such as hot flushes, fatigue, osteoporosis, and also reduces the chances of heart diseases thus, driving the growth of the hormone replacement therapy market in the forecast period.

Furthermore, one of the developments in the global market adopted by the leading market players is the introduction of gel-based formulation for estrogen patches and other products. The introduction of an estradiol gel formulation, which is mostly given for low doses and patients who are resistant to oral estrogen therapy, also contributes to the market's growth. Estradiol gels have acquired FDA approval for the treatment of menopausal symptoms with a percutaneous estradiol gel that is easy to administer and has minimal skin sensitivities. For instance, the medicine Estrasorb contains a liposomal formulation that is administered to the thigh's skin.

Restraints:

The lack of whichever hormone is being blocked or inactivated causes negative effects. These side effects are comparable to those associated with menopause, which is the body's natural decrease in estrogen production as it gets older. Hot flashes, nocturnal sweats, weight gain, vaginal dryness, and headache are all possible side effects. Hormone therapy is responsible for some adverse effects. Nausea, hair loss or thinning, muscular pains and joint discomfort, and, more gravely, blood clots and an increased risk of uterine/endometrial cancer are some of the symptoms that might occur thus, hampering the growth of the hormone replacement therapy market over the projected period.

Opportunities:

Increased unmet hormone replacement demands in developing countries, as well as growing awareness of the treatment of hormone abnormalities, drive pharmaceutical companies to introduce new advanced drugs to the global market. Furthermore, the growth in menopause and hormone deficiency problems in key countries has encouraged manufacturers to introduce new goods, such as combination therapy products, to replace the everyday usage of long-acting parenteral medications. For instance, Myovant Sciences announced that in May 2021, FDA has approved its medicine MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. This innovative drug was developed with association with Pfizer. Partnerships and the introduction of new hormone treatment therapies are expected to create opportunities for market players.

Segmentation Analysis of Hormone Replacement Therapy Market

By Route of Administration, the oral segment is anticipated to lead the growth of the hormone replacement therapy market during the projected period. Tablets are the most common as well as the simplest form of taking HRT. For men administration of testosterone is done orally, and for women, oral medication is the most common form of estrogen replacement therapy. Moreover, manufacturers have acknowledged the ease of oral administration of drugs, resulting in large-scale production of oral drugs thus, supporting the growth of the segment.

By HRT Type, the estrogen segment is expected to have the highest share of the HRT market over the analysis timeframe. Menopause symptoms are becoming more common among women all over the world. Many doctors will prescribe an estrogen-containing medicine for menopause. Hormone therapy can help alleviate the symptoms of menopause by replacing the declining estrogen. Estrogen may aid in the prevention of bone loss after menopause thus, strengthening the development of the segment.

By Medical Condition, the menopause segment is anticipated to dominate through the projected timeframe. Menopause isn't a disease. From a female's reproductive years to the next stage of life, it's a normal evolution. Many women pass through menopause without the need for treatment. However, if the transition generates uncomfortable or distracting symptoms, there are several therapy options. HRT is the most common method utilized to treat symptoms that arises due to menopause such as bone thinning, or osteoporosis, sleep problems, mood changes, and others. According to a study published in BioMed Central, by the year 2030, 1.2 billion women will be menopausal or postmenopausal. Furthermore, it is believed that roughly 40-50 million women in the United States have experienced vasomotor symptoms thus, supporting the growth of the segment.

Regional Analysis of Hormone Replacement Therapy Market

The North American region is anticipated to dominate the hormone replacement therapy market over the projected period. Individuals in the United States mostly suffer from endocrine-related disorders. The endocrine system has eight major glands that produce essential hormones that play an important role in the human body. Diabetes is the most common endocrine illness in the United States. According to the CDC's (Centers for Disease Control) National Diabetes Statistics Report for 2020, 34.2 million individuals in the United States, or 10.5 percent of the population, have diabetes. Diabetes has been diagnosed in an estimated 26.8 million persons or 10.2% of the population. Hormone supplements or HRT can be utilized to treat diabetes, if a very small amount of hormone is required for treatment thus, driving the growth of the market in this region.

The European region is anticipated to have the second-highest share of the HRT market throughout the forecasted timeframe. Several prominent medical research institutes are present in this region. The continuous R&D for the development of novel therapies that can treat cancer, hypothyroidism, and other hormone-related disorders has boosted the growth of the market. Hormone therapy is used to treat prostate and breast cancers along with other cancer treatment methods. Prostate cancer is the third predicted cause of cancer deaths in EU men with 78 800 deaths in 2020 and a rate of 10.0/100 000 (−7.1% since 2015). The increasing prevalence of cancerous diseases is stimulating the expansion of the HRT market in this region.

The HRT market in the Asia-Pacific region is projected to develop at a significant growth rate attributed to the growing awareness about the benefits of hormone replacement therapies. The number of diabetic patients in this region is quite high as compared to other regions. According to IDF, 90 million South East Asians were diagnosed with diabetes in 2021, this number is expected to reach 113 million by 2030. Approximately 10 billion USD was spent on diabetes treatments, and 747,000 deaths were caused by diabetes in 2021. The growing number of diabetic patients is the main factor propelling the growth of the hormone replacement therapy market in this region.

COVID-19 Impact Analysis of Hormone Replacement Therapy Market

The COVID-19 pandemic is expected to have a substantial impact on the market for home replacement therapy. A growing number of studies are being conducted to determine the effectiveness of hormone replacement treatment in COVID-19 infected patients. According to a study published in BMC Medicine in 2020, post-menopausal women infected with SARS-CoV-2 who were taking a regular dose of exogenous estradiol for post-menopausal complaints had a high survival rate. In April 2020, Stony Brook University began a phase 2 clinical trial to assess the impact of estrogen in lowering the severity of COVID-19 symptoms when compared to standard therapy, using estradiol delivered via a transdermal patch over seven days. As a result of the aforementioned characteristics, hormone replacement therapy is predicted to play a promising role in the development of innovative medicines for the effective treatment of SARS-CoV2 virus infection, potentially leading to market growth during the pandemic. Similarly, the usage of hormone replacement therapy is being widely utilized for the treatment of other medical disorders thus, supporting the development of the HRT market over the projected period.

Players Covered In Hormone Replacement Therapy Market

  • Ascendis Pharma A/S
  • Abbott Laboratories
  • Bayer AG
  • Merck KGaA
  • Pfizer Inc
  • Novartis AG
  • Noven Pharmaceuticals Inc
  • Novo Nordisk A/S
  • TherapeuticsMD Inc and other major players.

Key Industry Developments In Hormone Replacement Therapy Market

In August 2021, Ascendis Pharma A/S announced that the FDA has approved its medicine SKYTROFA for the treatment of pediatric patients aged one year and older who suffer from growth hormone insufficiency. This treatment was developed with the help of TransCon technology.

In April 2021, TherapeuticsMD Inc, and Theramex announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved BIJUVE® for use in the United Kingdom, and the Federal Agency for Medicines and Health Products (FAMHP) has approved BIJUVA® for use in Belgium.

Global Hormone Replacement Therapy Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD 28.06 Bn.

Forecast Period 2022-28 CAGR:

6.3%

Market Size in 2028:

USD 43.03 Bn.

Segments Covered:

By Type

  • Estrogen
  • Human Growth
  • Progestogen
  • Testosterone
  • Thyroid
  • Others

By Medical Condition

  • Hypertension
  • Growth Disorders
  • Infertility
  • Menopause
  • Cancer
  • Thyroid
  • Others

By Route of Administration

  • Oral
  • Injection
  • Surgical Intervention

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Launch of New Products by Key Market Players

Key Market Restraints:

  • Some Individuals May Suffer from Side Effects

Key Opportunities:

  • Growing Awareness Among Individuals About HRT

Companies Covered in the report:

  • Ascendis Pharma A/S, Abbott Laboratories, Bayer AG, Merck KGaA, Pfizer Inc, Novartis AG, Noven Pharmaceuticals Inc, Novo Nordisk A/S, TherapeuticsMD Inc and other major players.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Therapy Type
 3.2 By Indication
 3.3 By Route Of Administration
 3.4 By Distribution Channel

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  3.5.1 Drivers
  3.5.2 Restraints
  3.5.3 Opportunities
  3.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 4: Hormone Replacement Therapy Market by Therapy Type
 4.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 4.2 Hormone Replacement Therapy Market Overview
 4.3 Estrogen and Combinations Replacement Therapy
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size (2016-2028F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Estrogen and Combinations Replacement Therapy: Grographic Segmentation
 4.4 Growth Hormone Replacement Therapy
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size (2016-2028F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Growth Hormone Replacement Therapy: Grographic Segmentation
 4.5 Thyroid Hormone Replacement Therapy
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size (2016-2028F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Thyroid Hormone Replacement Therapy: Grographic Segmentation
 4.6 Testosterone Hormone Replacement Therapy
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size (2016-2028F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Testosterone Hormone Replacement Therapy: Grographic Segmentation

Chapter 5: Hormone Replacement Therapy Market by Indication
 5.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 5.2 Hormone Replacement Therapy Market Overview
 5.3 Menopause
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Menopause: Grographic Segmentation
 5.4 Hypothyroidism
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Hypothyroidism: Grographic Segmentation
 5.5 Male Hypogonadism
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Male Hypogonadism: Grographic Segmentation
 5.6 Growth Hormone Deficiency
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Growth Hormone Deficiency: Grographic Segmentation

Chapter 6: Hormone Replacement Therapy Market by Route Of Administration
 6.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 6.2 Hormone Replacement Therapy Market Overview
 6.3 Oral
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Oral: Grographic Segmentation
 6.4 Transdermal
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Transdermal: Grographic Segmentation
 6.5 Parenteral
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Parenteral: Grographic Segmentation

Chapter 7: Hormone Replacement Therapy Market by Distribution Channel
 7.1 Hormone Replacement Therapy Market Overview Snapshot and Growth Engine
 7.2 Hormone Replacement Therapy Market Overview
 7.3 Hospital Pharmacies
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospital Pharmacies: Grographic Segmentation
 7.4 Retails Pharmacies & Stores
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Retails Pharmacies & Stores: Grographic Segmentation
 7.5 Online Pharmacies
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Online Pharmacies: Grographic Segmentation

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Positioning
  8.1.2 Hormone Replacement Therapy Sales and Market Share By Players
  8.1.3 Industry BCG Matrix
  8.1.4 Ansoff Matrix
  8.1.5 Hormone Replacement Therapy Industry Concentration Ratio (CR5 and HHI)
  8.1.6 Top 5 Hormone Replacement Therapy Players Market Share
  8.1.7 Mergers and Acquisitions
  8.1.8 Business Strategies By Top Players
 8.2 ABBOTT LABORATORIES
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Operating Business Segments
  8.2.5 Product Portfolio
  8.2.6 Business Performance
  8.2.7 Key Strategic Moves and Recent Developments
  8.2.8 SWOT Analysis
 8.3 BAYER AG
 8.4 ELI LILLY AND COMPANY
 8.5 F. HOFFMANN-LA ROCHE LTD. (GENENTECH
 8.6 INC.)
 8.7 HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.)
 8.8 MERCK KGAA
 8.9 MYLAN N.V. (VIATRIS INC.)
 8.10 NOVARTIS INTERNATIONAL AG
 8.11 NOVO NORDISK A/S
 8.12 PFIZER INC.

Chapter 9: Global Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2016-2028
 9.1 Market Overview
 9.2 Historic and Forecasted Market Size By Therapy Type
  9.2.1 Estrogen and Combinations Replacement Therapy
  9.2.2 Growth Hormone Replacement Therapy
  9.2.3 Thyroid Hormone Replacement Therapy
  9.2.4 Testosterone Hormone Replacement Therapy
 9.3 Historic and Forecasted Market Size By Indication
  9.3.1 Menopause
  9.3.2 Hypothyroidism
  9.3.3 Male Hypogonadism
  9.3.4 Growth Hormone Deficiency
 9.4 Historic and Forecasted Market Size By Route Of Administration
  9.4.1 Oral
  9.4.2 Transdermal
  9.4.3 Parenteral
 9.5 Historic and Forecasted Market Size By Distribution Channel
  9.5.1 Hospital Pharmacies
  9.5.2 Retails Pharmacies & Stores
  9.5.3 Online Pharmacies

Chapter 10: North America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Therapy Type
  10.4.1 Estrogen and Combinations Replacement Therapy
  10.4.2 Growth Hormone Replacement Therapy
  10.4.3 Thyroid Hormone Replacement Therapy
  10.4.4 Testosterone Hormone Replacement Therapy
 10.5 Historic and Forecasted Market Size By Indication
  10.5.1 Menopause
  10.5.2 Hypothyroidism
  10.5.3 Male Hypogonadism
  10.5.4 Growth Hormone Deficiency
 10.6 Historic and Forecasted Market Size By Route Of Administration
  10.6.1 Oral
  10.6.2 Transdermal
  10.6.3 Parenteral
 10.7 Historic and Forecasted Market Size By Distribution Channel
  10.7.1 Hospital Pharmacies
  10.7.2 Retails Pharmacies & Stores
  10.7.3 Online Pharmacies
 10.8 Historic and Forecast Market Size by Country
  10.8.1 U.S.
  10.8.2 Canada
  10.8.3 Mexico

Chapter 11: Europe Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Therapy Type
  11.4.1 Estrogen and Combinations Replacement Therapy
  11.4.2 Growth Hormone Replacement Therapy
  11.4.3 Thyroid Hormone Replacement Therapy
  11.4.4 Testosterone Hormone Replacement Therapy
 11.5 Historic and Forecasted Market Size By Indication
  11.5.1 Menopause
  11.5.2 Hypothyroidism
  11.5.3 Male Hypogonadism
  11.5.4 Growth Hormone Deficiency
 11.6 Historic and Forecasted Market Size By Route Of Administration
  11.6.1 Oral
  11.6.2 Transdermal
  11.6.3 Parenteral
 11.7 Historic and Forecasted Market Size By Distribution Channel
  11.7.1 Hospital Pharmacies
  11.7.2 Retails Pharmacies & Stores
  11.7.3 Online Pharmacies
 11.8 Historic and Forecast Market Size by Country
  11.8.1 Germany
  11.8.2 U.K.
  11.8.3 France
  11.8.4 Italy
  11.8.5 Russia
  11.8.6 Spain

Chapter 12: Asia-Pacific Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Therapy Type
  12.4.1 Estrogen and Combinations Replacement Therapy
  12.4.2 Growth Hormone Replacement Therapy
  12.4.3 Thyroid Hormone Replacement Therapy
  12.4.4 Testosterone Hormone Replacement Therapy
 12.5 Historic and Forecasted Market Size By Indication
  12.5.1 Menopause
  12.5.2 Hypothyroidism
  12.5.3 Male Hypogonadism
  12.5.4 Growth Hormone Deficiency
 12.6 Historic and Forecasted Market Size By Route Of Administration
  12.6.1 Oral
  12.6.2 Transdermal
  12.6.3 Parenteral
 12.7 Historic and Forecasted Market Size By Distribution Channel
  12.7.1 Hospital Pharmacies
  12.7.2 Retails Pharmacies & Stores
  12.7.3 Online Pharmacies
 12.8 Historic and Forecast Market Size by Country
  12.8.1 China
  12.8.2 India
  12.8.3 Japan
  12.8.4 Southeast Asia

Chapter 13: South America Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Therapy Type
  13.4.1 Estrogen and Combinations Replacement Therapy
  13.4.2 Growth Hormone Replacement Therapy
  13.4.3 Thyroid Hormone Replacement Therapy
  13.4.4 Testosterone Hormone Replacement Therapy
 13.5 Historic and Forecasted Market Size By Indication
  13.5.1 Menopause
  13.5.2 Hypothyroidism
  13.5.3 Male Hypogonadism
  13.5.4 Growth Hormone Deficiency
 13.6 Historic and Forecasted Market Size By Route Of Administration
  13.6.1 Oral
  13.6.2 Transdermal
  13.6.3 Parenteral
 13.7 Historic and Forecasted Market Size By Distribution Channel
  13.7.1 Hospital Pharmacies
  13.7.2 Retails Pharmacies & Stores
  13.7.3 Online Pharmacies
 13.8 Historic and Forecast Market Size by Country
  13.8.1 Brazil
  13.8.2 Argentina

Chapter 14: Middle East & Africa Hormone Replacement Therapy Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Therapy Type
  14.4.1 Estrogen and Combinations Replacement Therapy
  14.4.2 Growth Hormone Replacement Therapy
  14.4.3 Thyroid Hormone Replacement Therapy
  14.4.4 Testosterone Hormone Replacement Therapy
 14.5 Historic and Forecasted Market Size By Indication
  14.5.1 Menopause
  14.5.2 Hypothyroidism
  14.5.3 Male Hypogonadism
  14.5.4 Growth Hormone Deficiency
 14.6 Historic and Forecasted Market Size By Route Of Administration
  14.6.1 Oral
  14.6.2 Transdermal
  14.6.3 Parenteral
 14.7 Historic and Forecasted Market Size By Distribution Channel
  14.7.1 Hospital Pharmacies
  14.7.2 Retails Pharmacies & Stores
  14.7.3 Online Pharmacies
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Saudi Arabia
  14.8.2 South Africa

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

Global Hormone Replacement Therapy Market

Base Year:

2021

Forecast Period:

2022-2028

Historical Data:

2016 to 2020

Market Size in 2021:

USD 28.06 Bn.

Forecast Period 2022-28 CAGR:

6.3%

Market Size in 2028:

USD 43.03 Bn.

Segments Covered:

By Type

  • Estrogen
  • Human Growth
  • Progestogen
  • Testosterone
  • Thyroid
  • Others

By Medical Condition

  • Hypertension
  • Growth Disorders
  • Infertility
  • Menopause
  • Cancer
  • Thyroid
  • Others

By Route of Administration

  • Oral
  • Injection
  • Surgical Intervention

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
  • South America (Brazil, Argentina, Rest of SA)

Key Market Drivers:

  • Launch of New Products by Key Market Players

Key Market Restraints:

  • Some Individuals May Suffer from Side Effects

Key Opportunities:

  • Growing Awareness Among Individuals About HRT

Companies Covered in the report:

  • Ascendis Pharma A/S, Abbott Laboratories, Bayer AG, Merck KGaA, Pfizer Inc, Novartis AG, Noven Pharmaceuticals Inc, Novo Nordisk A/S, TherapeuticsMD Inc and other major players.

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. HORMONE REPLACEMENT THERAPY MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. HORMONE REPLACEMENT THERAPY MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. HORMONE REPLACEMENT THERAPY MARKET COMPETITIVE RIVALRY
TABLE 005. HORMONE REPLACEMENT THERAPY MARKET THREAT OF NEW ENTRANTS
TABLE 006. HORMONE REPLACEMENT THERAPY MARKET THREAT OF SUBSTITUTES
TABLE 007. HORMONE REPLACEMENT THERAPY MARKET BY THERAPY TYPE
TABLE 008. ESTROGEN AND COMBINATIONS REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 009. GROWTH HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 010. THYROID HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 011. TESTOSTERONE HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
TABLE 012. HORMONE REPLACEMENT THERAPY MARKET BY INDICATION
TABLE 013. MENOPAUSE MARKET OVERVIEW (2016-2028)
TABLE 014. HYPOTHYROIDISM MARKET OVERVIEW (2016-2028)
TABLE 015. MALE HYPOGONADISM MARKET OVERVIEW (2016-2028)
TABLE 016. GROWTH HORMONE DEFICIENCY MARKET OVERVIEW (2016-2028)
TABLE 017. HORMONE REPLACEMENT THERAPY MARKET BY ROUTE OF ADMINISTRATION
TABLE 018. ORAL MARKET OVERVIEW (2016-2028)
TABLE 019. TRANSDERMAL MARKET OVERVIEW (2016-2028)
TABLE 020. PARENTERAL MARKET OVERVIEW (2016-2028)
TABLE 021. HORMONE REPLACEMENT THERAPY MARKET BY DISTRIBUTION CHANNEL
TABLE 022. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 023. RETAILS PHARMACIES & STORES MARKET OVERVIEW (2016-2028)
TABLE 024. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
TABLE 025. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 026. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 027. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 028. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 029. N HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 030. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 031. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 032. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 033. EUROPE HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 034. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 035. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 036. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 037. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 038. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 039. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 043. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 044. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 045. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY THERAPY TYPE (2016-2028)
TABLE 046. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY INDICATION (2016-2028)
TABLE 047. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 048. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 049. HORMONE REPLACEMENT THERAPY MARKET, BY COUNTRY (2016-2028)
TABLE 050. ABBOTT LABORATORIES: SNAPSHOT
TABLE 051. ABBOTT LABORATORIES: BUSINESS PERFORMANCE
TABLE 052. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 053. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. BAYER AG: SNAPSHOT
TABLE 054. BAYER AG: BUSINESS PERFORMANCE
TABLE 055. BAYER AG: PRODUCT PORTFOLIO
TABLE 056. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. ELI LILLY AND COMPANY: SNAPSHOT
TABLE 057. ELI LILLY AND COMPANY: BUSINESS PERFORMANCE
TABLE 058. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 059. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: SNAPSHOT
TABLE 060. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: BUSINESS PERFORMANCE
TABLE 061. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: PRODUCT PORTFOLIO
TABLE 062. F. HOFFMANN-LA ROCHE LTD. (GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. INC.): SNAPSHOT
TABLE 063. INC.): BUSINESS PERFORMANCE
TABLE 064. INC.): PRODUCT PORTFOLIO
TABLE 065. INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): SNAPSHOT
TABLE 066. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): BUSINESS PERFORMANCE
TABLE 067. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): PRODUCT PORTFOLIO
TABLE 068. HISAMITSU PHARMACEUTICAL CO. INC. (NOVEN PHARMACEUTICALS INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. MERCK KGAA: SNAPSHOT
TABLE 069. MERCK KGAA: BUSINESS PERFORMANCE
TABLE 070. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 071. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 071. MYLAN N.V. (VIATRIS INC.): SNAPSHOT
TABLE 072. MYLAN N.V. (VIATRIS INC.): BUSINESS PERFORMANCE
TABLE 073. MYLAN N.V. (VIATRIS INC.): PRODUCT PORTFOLIO
TABLE 074. MYLAN N.V. (VIATRIS INC.): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 074. NOVARTIS INTERNATIONAL AG: SNAPSHOT
TABLE 075. NOVARTIS INTERNATIONAL AG: BUSINESS PERFORMANCE
TABLE 076. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 077. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 077. NOVO NORDISK A/S: SNAPSHOT
TABLE 078. NOVO NORDISK A/S: BUSINESS PERFORMANCE
TABLE 079. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 080. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 080. PFIZER INC.: SNAPSHOT
TABLE 081. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 082. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 083. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY THERAPY TYPE
FIGURE 012. ESTROGEN AND COMBINATIONS REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 013. GROWTH HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 014. THYROID HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 015. TESTOSTERONE HORMONE REPLACEMENT THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 016. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY INDICATION
FIGURE 017. MENOPAUSE MARKET OVERVIEW (2016-2028)
FIGURE 018. HYPOTHYROIDISM MARKET OVERVIEW (2016-2028)
FIGURE 019. MALE HYPOGONADISM MARKET OVERVIEW (2016-2028)
FIGURE 020. GROWTH HORMONE DEFICIENCY MARKET OVERVIEW (2016-2028)
FIGURE 021. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY ROUTE OF ADMINISTRATION
FIGURE 022. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 023. TRANSDERMAL MARKET OVERVIEW (2016-2028)
FIGURE 024. PARENTERAL MARKET OVERVIEW (2016-2028)
FIGURE 025. HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 026. HOSPITAL PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 027. RETAILS PHARMACIES & STORES MARKET OVERVIEW (2016-2028)
FIGURE 028. ONLINE PHARMACIES MARKET OVERVIEW (2016-2028)
FIGURE 029. NORTH AMERICA HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. EUROPE HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. ASIA PACIFIC HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. MIDDLE EAST & AFRICA HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. SOUTH AMERICA HORMONE REPLACEMENT THERAPY MARKET OVERVIEW BY COUNTRY (2016-2028)

Please Wait...

Frequently Asked Questions :

What would be forecast period in the market research report?

The forecast period in the Hormone Replacement Therapy Market research report is 2022-2028.

Who are the key players in Hormone Replacement Therapy market?

Ascendis Pharma A/S, Abbott Laboratories, Bayer AG, Merck KGaA, Pfizer Inc, Novartis AG, Noven Pharmaceuticals Inc, Novo Nordisk A/S, TherapeuticsMD Inc and other major players.

What are the segments of Hormone Replacement Therapy market?

The Hormone Replacement Therapy market is segmented into Hormone Replacement Therapy Type, Medical Condition, Route of Administration, Region. By Hormone Replacement Therapy Type the market is categorized into Estrogen, Human Growth, Progestogen, Testosterone, Thyroid, Others. By Medical Condition the market is categorized into Hypertension, Growth Disorders, Infertility, Menopause, Cancer, Thyroid, Others. By Route of Administration the market is categorized into Oral, Injection, Surgical Intervention. By region, it is analyzed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain etc.), Asia-Pacific (China; India; Japan; Southeast Asia etc.), South America (Brazil; Argentina etc.), Middle East & Africa (Saudi Arabia; South Africa etc.).

What is the Hormone Replacement Therapy market?

Hormone replacement therapy (HRT) is the usage of hormones to replace natural hormones when the body's hormone production is insufficient. Thyroid and human growth hormone patients, for instance, may get hormone replacement treatment. Furthermore, HRT was often administered to menopausal women for the alleviation of symptoms such as hot flushes, night sweats, sleep difficulties, psychological and Genito-urinary disorders (urinary frequency and vaginal dryness), as well as the prevention of osteoporosis.

How big is the Hormone Replacement Therapy market?

Global Hormone Replacement Therapy Market Size Was Valued at USD 28.06 Billion in 2021, and is Projected to Reach USD 43.03 Billion by 2028, Growing at A CAGR of 6.3% From 2022 to 2028.